Canaccord Genuity maintains Beam Therapeutics at Buy, lowers price target to $78 from $79
Canaccord Genuity kept its Buy rating on Beam Therapeutics but reduced its price target to $78 from $79. This implies a 180.7% upside from the Nov 4 close of $27.79. Recent analyst price targets for the company range from $30 to $80.
How this was made

The 30-second read
Why it matters
The modest downgrade may lead to slight sell pressure.
Market read
Small but actionable insight for traders monitoring biotech analyst coverage.
What to watch
Potential upcoming catalyst not reflected in the target change.
Background
Analyst price target adjustments are routine but can influence short-term trading.
Ticker impact
Canaccord Genuity lowered Beam Therapeutics' price target to $78 from $79.
likely pressure as the market prices in the lower target
A 1.3% target cut signals reduced upside, which may temper bullish sentiment.
Market effects
Minor impact on the biotech sector as analysts adjust expectations.
Limited to U.S. biotech investors.
Low global relevance.
Counterpoint
The target cut may be overly cautious given recent trial data.
Key entities
- companyBeam Therapeutics
Biotech firm developing CRISPR-based gene editing therapies.
- analyst_firmCanaccord Genuity
Equity research firm providing coverage on BEAM.
